Johnson & Johnson (JNJ)vsInspireMD Inc (NSPR)
JNJ
Johnson & Johnson
$255.88
-3.63%
HEALTHCARE · Cap: $615.36B
NSPR
InspireMD Inc
$0.67
-2.10%
HEALTHCARE · Cap: $32.30M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 902638% more annual revenue ($97.93B vs $10.85M). JNJ leads profitability with a 21.5% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
NSPR
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for JNJ.
Margin of Safety
+46.3%
Fair Value
$3.21
Current Price
$0.67
$2.54 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 28.6%
Generating 3.4B in free cash flow
Reasonable price relative to book value
Revenue surging 122.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 1.0%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.
Bull Case : NSPR
The strongest argument for NSPR centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 122.2% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : NSPR
The primary concerns for NSPR are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NSPR is a hypergrowth play — different risk/reward profiles.
NSPR carries more volatility with a beta of 0.78 — expect wider price swings.
NSPR is growing revenue faster at 122.2% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 41/100), backed by strong 21.5% margins. NSPR offers better value entry with a 46.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →InspireMD Inc
HEALTHCARE · MEDICAL DEVICES · USA
InspireMD, Inc., a medical device company, is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular disease in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?